Nutriband CEO Outlines 2025 Achievements and 2026 Outlook in Shareholder Letter

Nutriband Inc. (NASDAQ: NTRB) announced that Chief Executive Officer Gareth Sheridan has published a letter to shareholders outlining key achievements during 2025 and providing perspective on the Company’s priorities and outlook for 2026. The update highlighted Nutriband’s continued focus on shareholder value, including disciplined capital management, a 25% preferred stock dividend issued in 2025, and progress toward reducing share price volatility with the expiration of IPO-era warrants in October 2026.

The Company also detailed significant advances for its lead product, AVERSA™ Fentanyl, which is being developed as an abuse-deterrent opioid transdermal patch. During 2025, Nutriband strengthened its intellectual property portfolio with new U.S. patent issuances, completed commercial manufacturing scale-up, and received FDA feedback through a Type C meeting to support its regulatory pathway. Additional milestones included inclusion in four Russell indexes and strategic transactions intended to support long-term growth as the Company continues advancing AVERSA™ Fentanyl toward commercialization.

This announcement matters because it demonstrates Nutriband's tangible progress in addressing the opioid crisis through pharmaceutical innovation. The development of abuse-deterrent formulations represents a critical public health initiative, as opioid abuse remains a significant national concern. The company's regulatory advancements with the FDA suggest potential for bringing a safer alternative to market, which could impact both patient care and the broader pharmaceutical landscape for pain management.

The implications of this update extend to investors, healthcare providers, and policymakers. For shareholders, the disciplined capital management and dividend issuance signal financial stability, while the progress on AVERSA™ Fentanyl indicates potential future revenue streams. The reduction of share price volatility through warrant expiration could make the stock more attractive to institutional investors. For the medical community, successful development of abuse-deterrent opioids could provide safer treatment options for chronic pain patients while reducing diversion and misuse.

Nutriband's strategic positioning in the transdermal pharmaceutical market, particularly with its proprietary AVERSA™ technology, represents a specialized approach to drug delivery that could be applied to other medications with abuse potential. The company's website at https://www.nutriband.com provides additional information about their technology platform. The regulatory pathway progress, including FDA feedback, suggests the company is navigating the complex approval process necessary for bringing new pharmaceutical products to market.

Looking ahead to 2026, Nutriband's priorities appear focused on advancing AVERSA™ Fentanyl toward commercialization while maintaining financial discipline. The expiration of IPO-era warrants in October 2026 represents a significant milestone that could stabilize the company's stock and potentially increase its appeal to a broader investor base. As the company continues to develop its abuse-deterrent technology, it positions itself at the intersection of pharmaceutical innovation and public health responsibility, addressing both medical needs and societal concerns around opioid medications.